Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Polymyalgia Rheumatica Market?

Over the recent years, there has been a notable surge in the market size of polymyalgia rheumatica. The market is projected to expand from $1.28 billion in the year 2024 to $1.36 billion in 2025, registering a compound annual growth rate (CAGR) of 5.9%. The historic growth is credited to heightened awareness among healthcare professionals, increased usage of corticosteroids, expansion of specialty clinics, the introduction of biologic therapies, and escalation in healthcare budgets.

The market for polymyalgia rheumatica is predicted to experience significant growth in the upcoming years, reaching a value of $1.72 billion by 2029 with a 6.1% compound annual growth rate (CAGR). This growth during the forecast period can be accredited to the increased use of biologics, the rise of precision medicine, swift drug approvals, comprehensive reimbursements, and the widening of clinical trials. Key trends for the forecast period encompass the development of combined therapies, progress in personalized medicine, the advancement of precision medicine, the incorporation of electronic health records, and the development in biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What Underlying Factors Are Supporting The Polymyalgia Rheumatica Market Growth?

The growth of the polymyalgia rheumatica market is expected to be fueled by an increasing demand for personalized medicine. This form of medical treatment is custom-made according to each individual’s genetic makeup, lifestyle, and specific health conditions, and it tends to yield more effective outcomes. What’s driving this demand is progress in genetic research, rising expectations from patients for treatment specifically designed for them, and better diagnostic technologies. Genetic research has deepened our understanding of individual genetic differences, enabling more tailored treatments that target specific genetic markers. By selecting drugs that are the most likely to be effective based on a patient’s unique traits, personalized medicine offers a treatment plan that is safer and more effective. For example, the Personalised Medicine Coalition reports that in February 2024, a US-based hospital and healthcare organization revealed that the Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from six new approvals in 2022. Thus, the rise in personalized medicine is propelling the growth of the polymyalgia rheumatica market.

How Does The Polymyalgia Rheumatica Market Differ By Segment?

The polymyalgia rheumaticamarket covered in this report is segmented –

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics

2) By Route Of Administration: Oral; Intravenous; Subcutaneous

3) By Patient Type: Adult; Geriatric; Periatric

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

What Are The Dominant Trends Currently Seen In The Polymyalgia Rheumatica Market?

Leading firms in the polymyalgia rheumatica market are focusing on interleukin-6 (IL-6) receptor blockers for targeted, effective treatments. These biologics inhibit IL-6, a key inflammatory cytokine in autoimmune diseases, reducing symptoms and improving patient quality of life. For instance, in February 2023, Regeneron Pharmaceuticals (US) and Sanofi (France) announced FDA approval of Kevzara (sarilumab) for adults with polymyalgia rheumatica who do not respond well to corticosteroids. Kevzara, the first biologic approved for this condition, blocks IL-6 signaling and showed significant remission rates in clinical trials. Administered via biweekly subcutaneous injection, Kevzara is also approved for rheumatoid arthritis.

Who Are The Global Leaders Steering The Polymyalgia Rheumatica Market Forward?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2025, By The Business Research Company

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model